Login to Your Account



Road to VALOR: One Trial Ends, Sunesis' AML Phase III Still On

By Randy Osborne
Staff Writer

Wednesday, July 31, 2013
Investors scratched their heads, but thet didn't seem to worry over-much about the halting of the monotherapy arm of a Phase II/III, Cardiff University-sponsored trial with vosaroxin, Sunesis Pharmaceutical Inc.'s quinolone derivative for acute myeloid leukemia (AML).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription